Overexpression of Evi-1 Oncoprotein Represses TGF-β Signaling in Colorectal Cancer

Overview

Journal Mol Carcinog

Specialties Molecular Biology
Oncology

Date 2011 Dec 14

PMID 22161860

Citations 24

Authors

Xiyun Deng

Yanna Cao

Yan Liu

Fazhi Li

Kamalanathan Sambandam

Srinivasan Rajaraman

Archibald S Perkins

Alan P Fields

Mark R Hellmich

Courtney M Townsend Jr

E Aubrey Thompson

Tien C Ko

Affiliations

Soon will be listed here.

Abstract

Human colorectal cancer (CRC) cells are resistant to the anti-proliferative effect of transforming growth factor-β (TGF-β), suggesting that disruption of TGF-β signaling plays an important role in colorectal carcinogenesis. Ecotropic virus integration site-1 (Evi-1) oncoprotein represses TGF-β signaling by interacting with Smads, but its role in CRC has not been established. The purpose of this study is to determine whether Evi-1 plays role(s) in CRCs and to characterize Evi-1 transcript(s) in CRCs. Evi-1 was overexpressed in 53% of human CRC samples, 100% of colon adenoma samples, and 100% of human colon cancer cell lines tested. Using 5' RACE, we cloned a novel Evi-1 transcript (Evi-1e) from a human CRC tissue and found that this novel transcript was expressed at a higher level in CRC tissues than in normal tissues and was the major Evi-1 transcript in CRCs. Transient Evi-1 transfection inhibited TGF-β-induced transcriptional activity and reversed the growth inhibitory effect of TGF-β in MC-26 mouse colon cancer cells. In conclusion, we have identified overexpression of Evi-1 oncoprotein as a novel mechanism by which a subset of human CRCs may escape TGF-β regulation. We have also identified a novel Evi-1 transcript, Evi-1e, as the major Evi-1 transcript expressed in human CRCs.

Citing Articles

A Preliminary Study on Transcriptional Regulation of SNP Site C-1888T in the Promoter Region of Human PLUNC Gene and Nasopharyngeal Carcinoma Susceptibility.

Liu B, Wang R, He Y Genet Res (Camb). 2024; 2024:5148918.

PMID: 39735594 PMC: 11671629. DOI: 10.1155/genr/5148918.

CRISPR-Cas9-mediated deletion enhancer of MECOM play a tumor suppressor role in ovarian cancer.

Chen Y, Jiang Q, Xue Y, Chen W, Hua M Funct Integr Genomics. 2024; 24(4):125.

PMID: 38995475 DOI: 10.1007/s10142-024-01399-8.

EVI1-mediated Programming of Normal and Malignant Hematopoiesis.

Lux S, Milsom M Hemasphere. 2023; 7(10):e959.

PMID: 37810550 PMC: 10553128. DOI: 10.1097/HS9.0000000000000959.

The Roles of Zinc Finger Proteins in Colorectal Cancer.

Iyer A, Shaik M, Raufman J, Xie G Int J Mol Sci. 2023; 24(12).

PMID: 37373394 PMC: 10299572. DOI: 10.3390/ijms241210249.

A distal super-enhancer activates oncogenic ETS2 via recruiting MECOM in inflammatory bowel disease and colorectal cancer.

Chen Y, Ying Y, Wang M, Ma C, Jia M, Shi L Cell Death Dis. 2023; 14(1):8.

PMID: 36609474 PMC: 9822945. DOI: 10.1038/s41419-022-05513-1.

References

Ten Dijke P, Goumans M, Itoh F, Itoh S . Regulation of cell proliferation by Smad proteins. J Cell Physiol. 2002; 191(1):1-16. DOI: 10.1002/jcp.10066. View

Morishita K, Parganas E, William C, Whittaker M, Drabkin H, Oval J . Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci U S A. 1992; 89(9):3937-41. PMC: 525606. DOI: 10.1073/pnas.89.9.3937. View

Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M . Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res. 2004; 28(8):791-803. DOI: 10.1016/j.leukres.2003.11.018. View

Alliston T, Ko T, Cao Y, Liang Y, Feng X, Chang C . Repression of bone morphogenetic protein and activin-inducible transcription by Evi-1. J Biol Chem. 2005; 280(25):24227-37. DOI: 10.1074/jbc.M414305200. View

Nitta E, Izutsu K, Yamaguchi Y, Imai Y, Ogawa S, Chiba S . Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP. Oncogene. 2005; 24(40):6165-73. DOI: 10.1038/sj.onc.1208754. View

Fears S, Mathieu C, Huang S, Rowley J, Nucifora G . Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci U S A. 1996; 93(4):1642-7. PMC: 39995. DOI: 10.1073/pnas.93.4.1642. View

Bei J, Li Y, Jia W, Feng B, Zhou G, Chen L . A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010; 42(7):599-603. DOI: 10.1038/ng.601. View

Zhou S, Buckhaults P, Zawel L, Bunz F, Riggins G, Dai J . Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci U S A. 1998; 95(5):2412-6. PMC: 19358. DOI: 10.1073/pnas.95.5.2412. View

Waite K, Eng C . From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nat Rev Genet. 2003; 4(10):763-73. DOI: 10.1038/nrg1178. View

10.

Balgobind B, Lugthart S, Hollink I, Arentsen-Peters S, van Wering E, de Graaf S . EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010; 24(5):942-9. DOI: 10.1038/leu.2010.47. View

11.

Akhurst R, Derynck R . TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol. 2001; 11(11):S44-51. DOI: 10.1016/s0962-8924(01)02130-4. View

12.

Riggins G, Kinzler K, Vogelstein B, Thiagalingam S . Frequency of Smad gene mutations in human cancers. Cancer Res. 1997; 57(13):2578-80. View

13.

Koos B, Bender S, Witt H, Mertsch S, Felsberg J, Beschorner R . The transcription factor evi-1 is overexpressed, promotes proliferation, and is prognostically unfavorable in infratentorial ependymomas. Clin Cancer Res. 2011; 17(11):3631-7. DOI: 10.1158/1078-0432.CCR-11-0175. View

14.

Aytekin M, Vinatzer U, Musteanu M, Raynaud S, Wieser R . Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5'-ends. Gene. 2005; 356:160-8. DOI: 10.1016/j.gene.2005.04.032. View

15.

Nolte F, Hofmann W . Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol. 2010; 6(3):445-55. DOI: 10.2217/fon.09.175. View

16.

Lugthart S, Figueroa M, Bindels E, Skrabanek L, Valk P, Li Y . Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood. 2010; 117(1):234-41. PMC: 3037746. DOI: 10.1182/blood-2010-04-281337. View

17.

Sunde J, Donninger H, Wu K, Johnson M, Pestell R, Rose G . Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res. 2006; 66(17):8404-12. DOI: 10.1158/0008-5472.CAN-06-0683. View

18.

Brooks D, Woodward S, Thompson F, Dos Santos B, Russell M, Yang J . Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer. 1996; 74(10):1518-25. PMC: 2074868. DOI: 10.1038/bjc.1996.583. View

19.

Stein S, Ott M, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A . Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010; 16(2):198-204. DOI: 10.1038/nm.2088. View

20.

Hoosein N, McKnight M, Levine A, Mulder K, Childress K, Brattain D . Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1. Exp Cell Res. 1989; 181(2):442-53. DOI: 10.1016/0014-4827(89)90101-8. View